New drug vimseltinib tested for tough GVHD cases

NCT ID NCT06619561

Recruiting now Disease control Sponsor: Deciphera Pharmaceuticals, LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 45 times

Summary

This study tests whether vimseltinib is safe and works for adults with moderate to severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Participants must have already tried at least two other treatments without success. They will take vimseltinib daily for about two years, and researchers will monitor side effects and how well the disease responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AdventHealth Orlando
RECRUITING

Orlando, Florida, 32804, United States
Avera Cancer Institute
RECRUITING

Sioux Falls, South Dakota, 57105, United States
City of Hope National Medical Center
RECRUITING

Duarte, California, 91010, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke University Hospital
RECRUITING

Durham, North Carolina, 27705, United States
Emory University Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
Henry Ford Cancer Institute
RECRUITING

Detroit, Michigan, 48202, United States
Intermountain Health
RECRUITING

Salt Lake City, Utah, 84143, United States
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Oncology Hematology Care Clinical Trials, LLC
RECRUITING

Cincinnati, Ohio, 45242, United States
Oregon Health and Science University
RECRUITING

Portland, Oregon, 97239, United States
Ronald Regan UCLA Medical Center
RECRUITING

Los Angeles, California, 90095, United States
St. David's South Austin Medical Center
RECRUITING

Austin, Texas, 78704, United States
The Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
Tristar Bone Marrow Transplant
RECRUITING

Nashville, Tennessee, 37203, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of California Irvine Health
RECRUITING

Orange, California, 92868-3201, United States
University of Illinois Medical Center - Hematology & Oncology
RECRUITING

Chicago, Illinois, 60612, United States
University of Kansas Cancer Center-Westwood
RECRUITING

Westwood, Kansas, 66205, United States
University of Kentucky Markey Cancer Center
RECRUITING

Lexington, Kentucky, 40536, United States
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States
Virginia Commonwealth University
RECRUITING

Richmond, Virginia, 23298, United States
Washington University School of Medicine - Siteman Cancer Center
RECRUITING

St Louis, Missouri, 63108, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

vimseltinib (a drug taken by mouth)

What this could lead to

If successful, this could offer a new treatment option for people with chronic GVHD who have not responded to other therapies.

What could go wrong

This is an early Phase 2 trial with only 48 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve symptoms.

Conditions

The condition(s) this trial relates to.

bronchial disorder bronchiolitis Bronchiolitis Obliterans Bronchiolitis Obliterans Syndrome chronic graft versus host disease Fibrosis graft versus host disease immune system disorder liver disorder lung disorder obstructive lung disease Organizing Pneumonia respiratory system disorder Sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)